IGF::OT::IGF: FY13: Phenotypic Screening of Smoking Cessation Drugs, N43DA-13-7

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N43DA130037
Agency Tracking Number: N43DA130037
Amount: $338,884.00
Phase: Phase I
Program: SBIR
Awards Year: 2013
Solitcitation Year: 2013
Solitcitation Topic Code: NIDA
Solitcitation Number: N/A
Small Business Information
AFASCI, INC.
522 Second Avenue, REDWOOD CITY, CA, 94063-3848
Duns: 160127655
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 XINMIN XIE
 (650) 784-5658
 SIMONXIE@AFASCI.COM
Business Contact
 XINMIN XIE
Phone: (650) 784-5658
Email: SIMONXIE@AFASCI.COM
Research Institution
 Stub
Abstract
Under this Small Business Innovation Research (SBIR) Phase I project, Research Topic 149, the Contractor shall develop predictive in vivo screening systems for phenotypic drug discovery for smoking cessation. The Contractor shall accomplish this throughthe following objectives: Objective 1- Evaluate a battery of tests aimed at examining various components of nicotine addiction to be used for phenotypic drug discovery and development of smoking cessation medications. Objective 2- Phenotypically profilefour FDA approved smoking cessation drugs (varenicline, bupropion, clonidine and nortriptyline, each tested at three doses) and two controls (positive drug at an appropriate dose and negative with vehicle) using the behavioral tests/assays validated inObjective 1. PUBLIC HEALTH RELEVANCE

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government